Back to top
more

Inogen (INGN)

(Real Time Quote from BATS)

$6.45 USD

6.45
770

-0.09 (-1.38%)

Updated Aug 5, 2025 09:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Shockwave Medical (SWAV) Up 6.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Inogen (INGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.

Zacks Equity Research

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 95% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Hold on to Inogen (INGN) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat

by Zacks Equity Research

Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.

Zacks Equity Research

Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold on to Inogen (INGN) Stock Now

by Zacks Equity Research

Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.

Zacks Equity Research

Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.

Zacks Equity Research

Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of -36.49% and 0.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inogen (INGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Inogen (INGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges

by Zacks Equity Research

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.

Zacks Equity Research

Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.

Zacks Equity Research

Inogen (INGN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 282.76% and 9.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Inogen (INGN) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

Inogen (INGN) Stock Loses 26.7% In Spite of Q2 Earnings Beat

by Zacks Equity Research

Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.

Zacks Equity Research

Inogen (INGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 269.23% and 15.22%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inogen (INGN) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.

Zacks Equity Research

Here's Why You Should Buy National Vision (EYE) Stock Now

by Zacks Equity Research

Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for June 29th

by Zacks Equity Research

AMN, INGN, SWBI, and CMRE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 29, 2021